“Deep in the forests of Germany, nestled neatly into the hollowed-out shells of acorns, live a smattering of ants who have stumbled upon a fountain of youth. They are born workers, but do not do much work. Their days are spent lollygagging about the nest, where their siblings shower them with gifts of food. They seem to elude the ravages of old age, retaining a durably adolescent physique, their outer shells soft and their hue distinctively tawny. Their scent, too, seems to shift, wafting out an alluring perfume that endears them to others. While their sisters, who have nearly identical genomes, perish within months of being born, these death-defying insects live on for years and years and years,” Katherine J. Wu writes.
A parasite gives its hosts the appearance of youth, and an unmatched social power in the colony.
Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect as a natural substance but are easier to manufacture. This opens up huge possibilities for drug discovery, which also has potential to rewrite the rulebook for pharmaceutical research.
Nature has a vast store of medicinal substances. “Over 50 percent of all drugs today are inspired by nature,” says Gisbert Schneider, Professor of Computer-Assisted Drug Design at ETH Zurich. Nevertheless, he is convinced that we have tapped only a fraction of the potential of natural products. Together with his team, he has successfully demonstrated how artificial intelligence (AI) methods can be used in a targeted manner to find new pharmaceutical applications for natural products. Furthermore, AI methods are capable of helping to find alternatives to these compounds that have the same effect but are much easier and therefore cheaper to manufacture.
And so the ETH researchers are paving the way for an important medical advance: we currently have only about 4000 basically different medicines in total. In contrast, estimates of the number of human proteins reach up to 400000, each of which could be a target for a drug. There are good reasons for Schneider’s focus on nature in the search for new pharmaceutical agents. “Most natural products are by definition potential active ingredients that have been selected via evolutionary mechanisms,” he says.
They found that insulin sensitivity can be restored within days of reducing excess production of the neurotransmitter GABA in the liver and that long-term treatment may lead to decreased appetite and weight loss.
New research suggests that reducing the production of a neurotransmitter in the liver could help normalize blood sugar and treat type 2 diabetes.
A 2010 study had found that people who were given zoledronate after experiencing hip fractures showed slightly reduced all-cause mortality compared to a control group. Patients who took the drug were at significantly lower risk for heart arrhythmias and pneumonia.
As this is a drug that is already being given to people, the choice to go back to genetically modified fruit flies, a much simpler model of aging, may seem counterintuitive. The team chose to test these insects for two principal reasons. The first is that Drosophila flies are a common subject of studies on basic aging pathways, which the researchers wished to explore. The second is simpler: Drosophila flies lack bones, making the bone-affecting properties of zoledronate irrelevant to the study.
Evidence suggests that what happens in one generation—diet, toxin exposure, trauma, fear—can have lasting effects on future generations. Scientists believe these effects result from epigenetic changes that occur in response to the environment and turn genes on or off without altering the genome or DNA sequence.
But how these changes are passed down through generations has not been understood, in part, because scientists have not had a simple way to study the phenomenon. A new study by researchers at the University of Maryland provides a potential tool for unraveling the mystery of how experiences can cause inheritable changes to an animal’s biology. By mating nematode worms, they produced permanent epigenetic changes that lasted for more than 300 generations. The research was published on July 9, 2021, in the journal Nature Communications.
“There’s a lot of interest in heritable epigenetics,” said Antony Jose, associate professor of cell biology and molecular genetics at UMD and senior author of the study. “But getting clear answers is difficult. For instance, if I’m on some diet today, how does that affect my children and grandchildren and so on? No one knows, because so many different variables are involved. But we’ve found this very simple method, through mating, to turn off a single gene for multiple generations. And that gives us a huge opportunity to study how these stable epigenetic changes occur.”
The Retrobiome, Cancer, And Aging — Roswell Park Comprehensive Cancer CtrThe Retrobiome, Cancer, And Aging — Dr. Andrei Gudkov, PhD, DSci, Roswell Park Comprehensive Cancer Center, joins me on Progress, Potential, And Possibilities Cornell University College of Veterinary Medicine #Cancer #Vaika #Genome #DnaDamage #ImmunoSenescence #Pets #Dogs #Health #Lifespan #LifeExtension #Inflammaging #Longevity #Aging #Oncology
Dr Andrei Gudkov, PhD, DSci, is a preeminent cancer researcher who serves as Senior Vice President, Research Technology and Innovation, Chair of the Department of Cell Stress Biology, and a member of the senior leadership team for National Cancer Institute (NCI) Cancer Center Support Grant at Roswell Park Comprehensive Cancer Center (https://www.roswellpark.org/andrei-gudkov).
Dr. Gudkov is responsible for building on the basic and translational research strengths of the Cell Stress Biology program in DNA damage and repair, photodynamic therapy, thermal and hypoxic stress and immune modulation.
Dr. Gudkov assists the President & CEO in developing and implementing strategic plans for new scientific programs and enhancing collaborations in research programs with regional and national academic centers as well as with industry.
Before joining Roswell Park, Dr. Gudkov served as chair of the Department of Molecular Genetics at Lerner Research Institute, Cleveland Clinic Foundation, and Professor of Biochemistry at Case Western University. He earned his doctoral degree in Experimental Oncology at the Cancer Research Center, USSR and a Doctorate of Science (D.Sci) in Molecular Biology at the Moscow State University, USSR. He has authored or co-authored over 135 scientific articles and holds 27 patents.
Dr. Gudkov is also an accomplished entrepreneur who founded Cleveland BioLabs, Inc., OncoTartis LLC and Everon Biosciences, Inc.
He holds the position of Director & Chief Scientific Advisor at Panacela Labs, Inc., Chief Scientific Officer of OncoTartis LLC, Chief Scientific Officer for Everon Biosciences, Inc., Chief Science Officer at Genome Protection, Inc. and Chief Scientific Officer of Cleveland BioLabs, Inc. Andrei V. Gudkov is also on the board of Incuron LLC.
Dr. Gudkov also serves on the Scientific Advisory Board and is author of the founding concept for the Vaika (https://www.vaika.org/) program, a not-for-profit charitable medical research organization with a mission to extend the health-span and life-span of domestic animals, with a focus on aged sled dogs.
The researchers hypothesized that due to abnormal excitement of the Meynert basal ganglia, SB enters the brain and activates anticholinergic action to suppress abnormal acetylcholine secretion of acetylcholine-memory-related circuits centered on the Meynert basal ganglia, eliminating the flashbacks.
Fortunately, a group of Japanese researchers from the Sogo PTSD Institute, Medical Corporation Sogokai, Japan led by Dr. Masanobu Sogo appear to have made a breakthrough in PTSD treatment.
They have identified a drug called trihexyphenidyl, that can significantly reduce the flashbacks and nightmares experienced by patients with PTSD, according to a study published in Brain and Behavior.
Trihexyphenidyl is a central anticholinergic drug used to manage disorders like parkinsonism, and alleviate several side-effects induced by drugs acting on the central nervous system (CNS). It acts by blocking the activity of a neurotransmitter, acetylcholine, in the CNS. Interestingly, it has been available for therapeutic use for around 66 years.
A previous study led by Lee found losing just 16 minutes of sleep could impact job performance. Her previous findings also show that minor sleep loss can decrease daily mindfulness, which is a critical recourse for managing stress and maintaining healthy routines.
Summary: Three consecutive nights of sleep loss can have a negative impact on both mental and physical health. Sleep deprivation can lead to an increase in anger, frustration, and anxiety. Additionally, those who experienced sleep loss reported a change in physical wellbeing, including gastrointestinal and respiratory problems.
Source: USF
All it takes is three consecutive nights of sleep loss to cause your mental and physical well-being to greatly deteriorate.
A new study published in Annals of Behavioral Medicine looked at the consequences of sleeping fewer than six hours for eight consecutive nights – the minimum duration of sleep that experts say is necessary to support optimal health in average adults.
This mapping of aetiological sources of cross-disorder overlap can guide future research aiming to identify specific mechanisms contributing to risk of physical conditions in people with ADHD, which could ultimately inform preventive and lifestyle intervention efforts. Our findings highlight the importance of assessing the presence of physical conditions in patients with ADHD.
Swedish Research Council; Swedish Brain Foundation; Swedish Research Council for Health, Working Life, and Welfare; Stockholm County Council; StratNeuro; EU Horizon 2020 research and innovation programme; National Institute of Mental Health.
They’re tiny machines that work on the nanoscale, being up to 100000 times smaller than the width of a human hair. These machines, otherwise known as nanorobotics, are set to augment the human race in unforeseen ways.
However, this microscopic technology has remained in the prototype phase for the past two decades, failing to truly live up to its promise, and lagging due to difficult manufacturing processes, a lack of standardization, and scant reviews of the available literature.
Picture a scenario where you’re ill and need to see your doctor. However, instead of giving you a pill or a shot, your doctor injects you with a swarm of tiny robots.
